To include your compound in the COVID-19 Resource Center, submit it here.

Forteo: Phase III data

A double-blind, international Phase III trial in 710 postmenopausal women with >=1 moderate or severe vertebral fracture thought to be the cause of back pain showed once-daily 20 µg subcutaneous Forteo missed the primary

Read the full 347 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE